Proteomics Defines Plasma Biomarkers for the Early Diagnosis of Biliary Atresia
Proteomics Defines Plasma Biomarkers for the Early Diagnosis of Biliary Atresia

Proteomics Defines Plasma Biomarkers for the Early Diagnosis of Biliary Atresia

J Proteome Res. 2024 Apr 3. doi: 10.1021/acs.jproteome.3c00873. Online ahead of print.

ABSTRACT

Early diagnosis of biliary atresia (BA) is crucial for improving the chances of survival and preserving the liver function of pediatric patients with BA. Herein, we performed proteomics analysis using data-independent acquisition (DIA) and parallel reaction monitoring (PRM) to explore potential biomarkers for the early diagnosis of BA compared to other non-BA jaundice cases. Consequently, we detected and validated differential protein expression in the plasma of patients with BA compared to the plasma of patients with intrahepatic cholestasis. Bioinformatics analysis revealed the enriched biological processes characteristic of BA by identifying the differential expression of specific proteins. Signaling pathway analysis revealed changes in the expression levels of proteins associated with an alteration in immunoglobulin levels, which is indicative of immune dysfunction in BA. The combination of polymeric immunoglobulin receptor expression and immunoglobulin lambda variable chain (IGL c2225_light_IGLV1-47_IGLJ2), as revealed via machine learning, provided a useful early diagnostic model for BA, with a sensitivity of 0.8, specificity of 1, accuracy of 0.89, and area under the curve value of 0.944. Thus, our study identified a possible effective plasma biomarker for the early diagnosis of BA and could help elucidate the underlying mechanisms of BA.

PMID:38569191 | DOI:10.1021/acs.jproteome.3c00873